Guangdong Provincial Drug Exchange has announced an adjustment to the pricing of certain medical consumables on its third-party drug electronic trading platform. This initiative aims to optimize pricing rules, enhance price monitoring, and ensure fair and transparent transactions.

Key Policy Highlights

1. Pricing Adjustment
   • Effective Date: The adjusted pricing for specific medical consumables will take effect from April 9, 2025.
   • Product Details: Detailed information on the adjusted products is provided in the attachment for reference.
2. Preparation Requirements
   • Transition Readiness: Relevant units need to prepare for online procurement and price transition of related products according to the actual situation.
3. Policy Background
   • Basis: The adjustment is conducted in accordance with the “Notice on Optimizing and Perfecting the Listing Rules for Drugs and Consumables and Strengthening Price Monitoring” (粤医保函〔2023〕144号) and the “Announcement on the Implementation of Medical Consumable Listing Procurement on the Third-Party Drug Electronic Trading Platform of Guangdong Province”.

Policy Orientation and Industry Implications
The pricing adjustment policy reflects Guangdong’s strategic focus on:

• Transparency: Enhancing transparency in medical consumable pricing through public disclosure.
• Fair Pricing: Ensuring medical institutions can access products at fair and reasonable prices.
• Market Efficiency: Promoting efficient distribution and procurement processes to support healthcare delivery.

Conclusion
Guangdong’s approach to adjusting medical consumable pricing sets a benchmark for regional medical product management, emphasizing transparency, fair pricing, and efficient distribution. Medical product enterprises should align with these guidelines to ensure smooth operations and contribute to healthcare efficiency.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1907730520356163584

The Guangdong Provincial Drug Exchange has issued a stern warning against entities or individuals impersonating the center to conduct pharmaceutical, medical device, and vaccine business and agency activities. This initiative aims to protect the normal order of drug procurement and trading and prevent fraud.

Key Policy Highlights

1. Functional Positioning
   • Core Functions: The exchange emphasizes its role in facilitating drug transactions and does not engage in commercial activities.
   • Policy Compliance: All activities are strictly conducted in accordance with policy requirements.
2. Anti-Fraud Measures
   • Public Warning: A clear warning to the public about potential fraud activities.
   • Legal Action: The exchange reserves the right to pursue legal action against those who impersonate its name.
3. Public Engagement
   • Vigilance: Encourages the public to remain alert and verify information through official channels.
   • Supervision: Invites public participation in maintaining transaction order by reporting suspicious activities.

Policy Orientation and Industry Implications
The anti-fraud warning reflects Guangdong’s strategic focus on:

• Market Integrity: Ensuring the normal order of drug procurement and trading.
• Transparency: Promoting clear communication to prevent misinformation and fraud.
• Public Protection: Safeguarding the public from fraudulent activities through awareness and vigilance.

Conclusion
Guangdong Provincial Drug Exchange’s anti-fraud warning underscores its commitment to maintaining market integrity and protecting the public from deception. Stakeholders and the public should remain vigilant and verify information through official channels to avoid fraud.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1907735780852240384